Tumorigenicity cell-base therapies

Importantly, knowledge of intestinal bile acid transport and metabolism, coupled with increased understanding of the mechanistic basis of the pro-tumorigenic activity of bile acids against CRC cells in vitro, has recently led to development and testing of bile acid-based treatment and prevention strategies for sporadic and inflammatory bowel-disease-associated CRC. Existing evidence that manipulation of the luminal secondary bile acid pool and/or therapy with ursodeoxycholic acid (UDCA) may have promise for prevention of CRC will be assessed. 

Tumorigenicity studies are also needed for certain cell therapy products based on the specific product attributes and clinical indications. Somatic cell therapy includes cells from various sources such as adult cells derived from the individual being treated (autologous), cells donated from one human to another (allogeneic), and cells from an animal source and used for human treatment (xenogeneic). Stem cell therapy includes cells derived from a variety of adult... 

---